

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) ~~Use of sulfated glycosaminoglycans having an anticoagulant activity of 100 BP units/mg or less for the manufacture of a pharmaceutical preparation~~ A method for prophylactic priming or curative treatment of the cervix and the myometrium for establishing effective labor in women, comprising the step of:

administering to a pregnant woman an effective amount of at least one sulfated glycosaminoglycan having an anticoagulant activity of 100 BP units/mg or less.

2. (Currently Amended) ~~Use of a glycosaminoglycan~~ The method according to claim 1, which belongs to wherein the at least one glycosaminoglycan comprises at least one glycosaminoglycan selected from the group consisting of heparan sulfates sulfate and depolymerised heparan sulfates sulfate.

3. (Currently Amended) ~~Use of a glycosaminoglycan~~ The method according to claim 1, which belongs to wherein the at least one glycosaminoglycan comprises at least one glycosaminoglycan selected from the group consisting of chondroitin sulfates sulfate and depolymerised chondroitin sulfates sulfate.

4. (Currently Amended) ~~Use of a glycosaminoglycan~~ The method according to claim 1, ~~which belongs to~~ wherein the at least one glycosaminoglycan comprises at least one glycosaminoglycan selected from the group consisting of dermatan sulfates sulfate or and depolymerised dermatan sulfates sulfate.

5. (Currently Amended) ~~Use of a glycosaminoglycan~~ The method according to claim 1, ~~which belongs to~~ wherein the at least one glycosaminoglycan comprises ~~the group consisting of~~ depolymerised heparins heparin having an average molecular weight below 10 000 Da, ~~preferably not higher than 6000 Da.~~

6. (Currently Amended) ~~Use of a glycosaminoglycan~~ The method according to any one of claims 1-5, ~~having~~ wherein the at least one glycosaminoglycan has an anticoagulant activity of 30 BP units/mg or less.

7. (Currently Amended) ~~Use of a glycosaminoglycan~~ The method according to claim 2, ~~having,~~ wherein the at least one glycosaminoglycan has a sulfate/hexosamine ratio below 1.0 and an anticoagulant activity of 10 BP units/mg or less.

8. (Currently Amended) ~~Use of a glycosaminoglycan according to claim 1~~ The method according to claim 1, wherein the at least one glycosaminoglycan is administered in combination with oxytocin.

9. (Currently Amended) ~~Use of a glycosaminoglycans according to claim 1 for the manufacture of~~ The method according to claim 1, wherein the at least one glycosaminoglycan is administered topically in a topical pharmaceutical preparation.

10. (Currently Amended) ~~Use of a glycosaminoglycans according to claim 1 for the manufacture of~~ The method according to claim 1, wherein the at least one glycosaminoglycan is administered in a parenteral pharmaceutical preparation.

11. (New) The method according to claim 5, wherein the at least one glycosaminoglycan comprises depolymerised heparin having a molecular weight not higher than 6,000 Da.